We saw a sharp intraday fall in EVERESTO.BO stock on 04 Mar 2026 after heavy selling pushed the price to INR 296.70, down 18.19% from the previous close. Trading volume surged to 68,222 shares against an average of 4,453, a relative volume of 15.32, signalling unusually high participation. The drop follows a recent pullback from the 50‑day average of INR 427.42 and raises immediate questions on valuation, liquidity and near‑term momentum for Everest Organics Limited on the BSE.

Intraday price action for EVERESTO.BO stock

EVERESTO.BO stock opened at INR 344.50 and traded between INR 290.15 and INR 344.50 today. The stock closed near INR 296.70, down INR 65.95 from the previous close of INR 362.65. Volume hit 68,222 versus an average of 4,453, indicating outsized flows on the sell‑off.

Valuation and fundamentals of EVERESTO.BO stock

Everest Organics shows a trailing EPS of INR 6.35 and a reported PE of 46.72. Price to book stands at 3.97 and market cap is INR 2,881,113,064.00. Revenue per share is INR 193.96 and book value per share is INR 74.67, which keeps valuation above the healthcare sector average PE of 38.80.

Technical snapshot and trading signals for EVERESTO.BO stock

Momentum indicators show stress: RSI is 28.83 (oversold) and MACD histogram is negative. ADX at 32.64 indicates a strong trend to the downside. Bollinger middle band sits at INR 381.48 and the lower band at INR 317.70, so price is below the middle band and trending toward the lower bound.

Meyka AI rates EVERESTO.BO with a score out of 100

Meyka AI rates EVERESTO.BO with a score out of 100: 67.24 (Grade B | Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s grade reflects mixed fundamentals and recent volatility, not investment advice.

Meyka AI’s forecast and price targets for EVERESTO.BO stock

Meyka AI’s forecast model projects a monthly target of INR 395.08, a quarterly target of INR 606.20, and a 12‑month projection of INR 307.84. Against the current INR 296.70, the 12‑month projection implies a 3.76% upside, while the monthly projection implies a 33.17% upside. Forecasts are model‑based projections and not guarantees.

Risks, sector context and near-term outlook for EVERESTO.BO stock

Key risks include stretched receivables with days sales outstanding at 223.72 and interest coverage at 2.12. Debt to equity is 0.68, higher than many healthcare peers. The healthcare sector PE averages 38.80, making EVERESTO.BO relatively expensive on PE. Given current stress, traders should watch the year low at INR 222.00 and year high at INR 536.40 for support and resistance.

Final Thoughts

EVERESTO.BO stock is a clear intraday loser on 04 Mar 2026, falling to INR 296.70 with heavy volume and oversold technicals. Fundamentals show modest profitability with EPS INR 6.35, but valuation remains rich at PE 46.72 versus the healthcare average. Meyka AI’s grade (Score 67.24, Grade B, HOLD) signals mixed signals: stable revenue per share but stretched receivables and moderate leverage. Meyka AI’s forecast model projects INR 307.84 over 12 months, an implied upside of 3.76% from today. Given the high relative volume and RSI at 28.83, short‑term volatility is likely to remain elevated; traders should use tight risk controls and watch support at INR 290.15 and INR 222.00. For an updated quote, see the company site and exchange pages and our Meyka stock page for real‑time analytics

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.